What is the typical dosing regimen for Imipramine (Imipramine Hydrochloride) in adults, elderly patients with impaired renal function, and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Imipramine Hydrochloride Dosing

For depression in adults, start hospitalized patients at 100 mg/day in divided doses, gradually increasing to 200 mg/day as needed, while outpatients should begin at 75 mg/day and increase to 150 mg/day, with elderly patients and adolescents requiring substantially lower starting doses of 30-40 mg/day. 1

Adult Dosing for Depression

Hospitalized Patients

  • Starting dose: 100 mg/day in divided doses 1
  • Titration: Gradually increase to 200 mg/day as required 1
  • If no response after 2 weeks: Increase to 250-300 mg/day 1
  • Maximum recommended dose: 300 mg/day 1
  • Maintenance: 50-150 mg/day after remission 1

Outpatients

  • Starting dose: 75 mg/day 1
  • Target dose: Increase to 150 mg/day 1
  • Maximum recommended dose: 200 mg/day (doses over 200 mg/day are not recommended for outpatients) 1
  • Maintenance: 50-150 mg/day 1

Critical consideration: Outpatients require lower doses than hospitalized patients due to less intensive monitoring, and exceeding 200 mg/day in the outpatient setting is explicitly not recommended. 1

Elderly Patients and Adolescents

Lower dosages are mandatory for elderly patients and adolescents due to increased sensitivity and risk of adverse effects. 1

  • Starting dose: 30-40 mg/day 1
  • Maximum dose: Generally not necessary to exceed 100 mg/day 1
  • Maintenance: Adjust based on clinical response and tolerability 1

Special Pharmacokinetic Considerations in Elderly

Elderly patients exhibit dose-dependent, non-linear kinetics with imipramine, where increased doses result in disproportionately higher plasma levels of the active metabolite desipramine. 2, 3 This phenomenon makes dose adjustments particularly unpredictable in older adults, as a modest dose increase can lead to unexpectedly high drug concentrations and increased risk of toxicity. 2 Plasma level monitoring may be difficult to interpret due to this saturation of hydroxylation pathways. 2, 3

Pediatric Dosing for Childhood Enuresis

For nocturnal enuresis in children aged 6 years and older, start with 25 mg/day given one hour before bedtime. 1

Titration Schedule

  • Initial dose (age ≥6 years): 25 mg/day one hour before bedtime 1
  • If inadequate response after 1 week:
    • Children under 12 years: Increase to 50 mg nightly 1
    • Children over 12 years: May receive up to 75 mg nightly 1
  • Maximum daily dose: 75 mg (doses greater than 75 mg do not enhance efficacy and increase side effects) 1
  • Absolute maximum: 2.5 mg/kg/day should not be exceeded 1

Timing Optimization

For early night bedwetters, divided dosing may be more effective: 25 mg in mid-afternoon, repeated at bedtime. 1 This approach addresses the timing of enuresis episodes more effectively than a single bedtime dose.

Duration and Discontinuation

  • After adequate therapeutic trial with favorable response: Institute a drug-free period 1
  • Discontinuation method: Taper gradually rather than abrupt cessation to reduce relapse tendency 1
  • Important caveat: Children who relapse when the drug is discontinued do not always respond to subsequent treatment courses 1

Safety Monitoring in Children

ECG changes of unknown significance have been reported in pediatric patients receiving doses of 5 mg/kg/day (twice the maximum recommended dose). 1 This underscores the importance of not exceeding 2.5 mg/kg/day in children.

The safety and effectiveness of imipramine as temporary adjunctive therapy for nocturnal enuresis in children less than 6 years of age has not been established. 1

Renal Impairment Considerations

While the FDA label does not provide specific dosing adjustments for renal impairment, elderly patients often have declining renal function with age, which contributes to the need for lower doses in this population. 1 The dose-dependent kinetics observed in elderly patients may be partially attributable to reduced renal clearance. 2, 3

General Dosing Principles

Initiation Strategy

Dosage should be initiated at a low level and increased gradually, with careful monitoring of clinical response and any evidence of intolerance. 1 This "start low, go slow" approach is particularly critical given the non-linear pharmacokinetics and potential for disproportionate increases in active metabolite levels. 2, 3

Maintenance Therapy

Following remission, maintenance medication may be required for a longer period at the lowest dose that will maintain remission. 1 This emphasizes the importance of finding the minimum effective dose rather than maintaining patients on higher acute treatment doses.

Drug Interactions Affecting Dosing

Concomitant treatment with perphenazine (8-16 mg/day) or levomepromazine causes marked rises in imipramine levels, particularly affecting desipramine concentrations. 2, 3 This occurs due to inhibition of hydroxylation pathways, necessitating dose reduction when these medications are combined.

Common Pitfalls to Avoid

  1. Avoid rapid dose escalation in elderly patients: The non-linear kinetics mean that doubling the dose can result in much more than double the plasma concentration. 2, 3

  2. Do not exceed 200 mg/day in outpatients: This ceiling exists because outpatients lack the close supervision available in hospital settings. 1

  3. Do not abruptly discontinue in children with enuresis: Gradual tapering reduces relapse risk. 1

  4. Do not exceed 2.5 mg/kg/day in children: Higher doses are associated with ECG changes and do not improve efficacy for enuresis. 1

  5. Monitor for therapeutic response timing: If no response occurs after 2 weeks at 200 mg/day in hospitalized patients, dose escalation to 250-300 mg/day may be warranted, but continued lack of response should prompt reconsideration of the treatment approach. 1

References

Related Questions

What adjustments can be made to the medication regimen of a 16-year-old female patient with bipolar disorder, currently taking Abilify (aripiprazole) 7.5mg daily, Adderall (dextroamphetamine) 30mg XR daily, mirtazapine 3.75mg nightly, trazodone 25mg nightly, and hydroxyzine pamoate 25mg daily as needed, to address significant weight gain and menstrual irregularity?
What are the potential risks and management strategies for a patient on a complex medication regimen including multiple antipsychotics (e.g., Zyprexa [Olanzapine], Abilify [Aripiprazole], Lurasidone), antidepressants (e.g., Trazodone, Mirtazapine, Imipramine [Imitriptyline]), and a stimulant (Focalin LA [Dexmethylphenidate])?
How to manage a complex medication regimen including aripiprazole, trazodone, buspirone, mirtazapine, benztropine, lurasidone, dexmethylphenidate, propranolol, and sumatriptan?
What adjustments should be made to the medication regimen of a 7-year-old patient with Attention Deficit Hyperactivity Disorder (ADHD) and Post-Traumatic Stress Disorder (PTSD) taking clonidine (clonidine) 0.1mg four times a day (QID), trazodone (trazodone) 50mg 1.5 tablets at bedtime, trileptal (oxcarbazepine) 150mg orally twice a day (BID), seroquel (quetiapine) 50mg 1.5 tablets orally every night at bedtime, and qelbree (viloxazine) 150mg orally every morning, who has recently experienced increased hyperactivity, distractibility, and talkativeness after a dosage increase of qelbree?
What is the equivalent dose of Wellbutrin (bupropion) for a patient taking 10mg of Lexapro (escitalopram)?
What are the guidelines for using Vraylar (cariprazine) in an adult patient with schizophrenia or bipolar disorder?
What does the presence of micromegakaryocytes (large platelet-producing cells) in a peripheral blood smear indicate?
What is the recommended treatment for a patient with stage 3 or higher triple negative (TN) neoadjuvant breast cancer?
What are the potential causes and management options for a patient presenting with cerebellar ataxia and dysautonomia?
What is the appropriate antibiotic treatment for a 60-year-old male with an infected ingrown groin hair?
What is the recommended use and dosage of Aripiprazole (Abilify) for a patient with schizophrenia, bipolar disorder, or major depressive disorder who has not responded to other treatments?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question